2020
The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial
Steiner AZ, Hansen KR, Barnhart KT, Cedars MI, Legro RS, Diamond MP, Krawetz SA, Usadi R, Baker VL, Coward RM, Huang H, Wild R, Masson P, Smith JF, Santoro N, Eisenberg E, Zhang H, Network R. The effect of antioxidants on male factor infertility: the Males, Antioxidants, and Infertility (MOXI) randomized clinical trial. Fertility And Sterility 2020, 113: 552-560.e3. PMID: 32111479, PMCID: PMC7219515, DOI: 10.1016/j.fertnstert.2019.11.008.Peer-Reviewed Original ResearchConceptsMonths of treatmentMale factor infertilityFactor infertilityLive birthsSemen parametersPlacebo groupPrimary outcomeSperm concentrationPlacebo-controlled trialLive birth rateCumulative live birthDNA fragmentationFemale partnersSperm DNA fragmentation indexLycopene dailyVivo pregnancyClomiphene citrateSecondary outcomesEntire cohortAsthenospermic menFertility centerIntrauterine inseminationMonth 4Tubal patencyClinical trials
2018
Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome
Christianson MS, Legro RS, Jin S, Eisenberg E, Diamond MP, Hansen KR, Vitek W, Styer AK, Casson P, Coutifaris C, Christman GM, Alvero R, Puscheck EE, Christy AY, Sun F, Zhang H, Polotsky AJ, Santoro N. Comparison of sonohysterography to hysterosalpingogram for tubal patency assessment in a multicenter fertility treatment trial among women with polycystic ovary syndrome. Journal Of Assisted Reproduction And Genetics 2018, 35: 2173-2180. PMID: 30194618, PMCID: PMC6289919, DOI: 10.1007/s10815-018-1306-2.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeSaline infusion sonohysterographyTubal patencyClinical pregnancyOvary syndromePolycystic Ovary Syndrome IITubal patency assessmentClinical pregnancy rateDuration of infertilityAcceptable imaging modalityIntrauterine pregnancyClomiphene citrateEctopic pregnancyInfertile womenResultsAmong womenMultivariable analysisPatency assessmentTreatment armsTreatment trialsPregnancy rateMethodsSecondary analysisHysterosalpingogramLarge cohortTubes patentPatency
2015
Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes
Steiner AZ, Diamond MP, Legro RS, Schlaff WD, Barnhart KT, Casson PR, Christman GM, Alvero R, Hansen KR, Geisler WM, Thomas T, Santoro N, Zhang H, Eisenberg E, Network R. Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes. Fertility And Sterility 2015, 104: 1522-1526. PMID: 26413816, PMCID: PMC4663111, DOI: 10.1016/j.fertnstert.2015.08.022.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, BacterialBiomarkersChi-Square DistributionChlamydia InfectionsChlamydia trachomatisEnzyme-Linked Immunosorbent AssayFallopian TubesFemaleHumansImmunoglobulin GInfertility, FemaleLinear ModelsLive BirthMultivariate AnalysisOdds RatioPredictive Value of TestsPregnancyPregnancy RatePregnancy, EctopicReproductive Techniques, AssistedRisk AssessmentRisk FactorsSerologic TestsTreatment OutcomeUltrasonographyYoung AdultConceptsEctopic pregnancySeropositive womenInfertile womenTubal patencyLive birthsPolycystic Ovary Syndrome IIChlamydia trachomatis seropositivityMultiple Intrauterine GestationsPatent fallopian tubesEnzyme-linked immunosorbentCurrent alcohol useC. trachomatis elementary bodiesOvarian stimulationCohort studyIntrauterine gestationPregnancy outcomesPrimary outcomeTreatment medicationsPatent tubesSmoking statusOutpatient clinicIgG3 antibodiesFallopian tubeRelative riskMAIN OUTCOME